logo
Медицинский вестник
Северного Кавказа
Научно-практический журнал
Зарегистрирован в Федеральной службе
по надзору за соблюдением законодательства
в сфере массовых коммуникаций
и охране культурного наследия
ПИ №ФС77-26521 от 7 декабря 2006 года
ISSN 2073-8137
rus
русский
eng
english

Поиск по сайту




Адрес редакции
355017, Ставрополь, улица Мира, 310.

Телефоны
(8652) 35-25-11, 35-32-29.

E-mail
medvestnik@stgmu.ru

Рейтинг@Mail.ru

Мигрень и тревожно-депрессивные расстройства

[Обзоры]
Гарабова Наида Исагаджиевна; Трубе Эллина Евгеньевна; Кириллова Екатерина Алексеевна; Семина Елизавета Евгеньевна; Магомедова Инесса Гаджиевна;

Мигрень – одна из самых частых причин головных болей, которая значительно снижает качество жизни людей, чаще поражает женщин после полового созревания и, в связи с трудностями диагностики и низкой приверженностью к лечению пациентов, недостаточно диагностируется у мужчин. Мигрень ассоциируется с психическими расстройствами, особенно с тревогой и депрессией, которые могут ухудшить тяжесть ее течения и прогноз. Исследования показывают тесную связь между хронической мигренью и тревожными расстройствами из-за общности патогенеза, поэтому ранняя оценка и междисциплинарное лечение способствуют целостному подходу к управлению неврологическим и психическим здоровьем.

Скачать

Список литературы:
1. Alwhaibi M., Balkhi B., AlRuthia Y. Anxiety and depression and health-related quality of life among adults with migraine: a National Population-Based Study. Frontiers In Public Health. 2023;11:1241800. https://doi.org/10.3389/fpubh.2023.1241800
2. Duan S., Ren Z., Xia H., Wang Z., Zheng T. [et al.]. Associations between anxiety, depression with migraine, and migraine-related burdens. Frontiers In Neurology. 2023;14:1090878. https://doi.org/10.3389/fneur.2023.1090878
3. Kumar R., Asif S., Bali A., Dang A. K., Gonzalez D. A. The Development and Impact of Anxiety With Migraines: A Narrative Review. Cureus. 2022;14(6):e26419. https://doi.org/10.7759/cureus.26419
4. Ornello R., Andreou A. P., De Matteis E., Jürgens T. P., Minen M. T. [et al.]. Resistant and refractory migraine: clinical presentation, pathophysiology, and management. EBioMedicine. 2024;99:104943. https://doi.org/10.1016/j.ebiom.2023.104943
5. Ruscheweyh R., Lehnen N., Henningsen P. Migräne und psychosomatische Komorbiditäten [Migraine and psychosomatic comorbidity]. Fortschritte Der NeurologiePsychiatrie. 2024;92(7-08):304-309. https://doi.org/10.1055/a-2331-0840
6. Karimi L., Wijeratne T., Crewther S. G., Evans A. E., Ebaid D. [et al.]. The Migraine-Anxiety Comorbidity Among Migraineurs: A Systematic Review. Frontiers In Neurology. 2021;11:613372. https://doi.org/10.3389/fneur.2020.613372
7. Wachowska K., Bliźniewska-Kowalska K., Sławek J., Adamczyk-Sowa M., Szulc A. [et al.]. Common pathomechanism of migraine and depression. Wspólny patomechanizm migreny i depresji. Psychiatria Polska. 2023;57(2):405-419. https://doi.org/10.12740/PP/OnlineFirst/143982
8. de Vries Lentsch S., Louter M. A., van Oosterhout W., van Zwet E. W., van Noorden [et al.]. Depressive symptoms during the different phases of a migraine attack: A prospective diary study. Journal of Affective Disorders. 2022;297:502-507. https://doi.org/10.1016/j.jad.2021.10.046
9. Frimpong-Manson K., Ortiz Y. T., McMahon L. R., Wilkerson J. L. Advances in understanding migraine pathophysiology: a bench to bedside review of research insights and therapeutics. Frontiers in Molecular Neuroscience. 2024;17:1355281. https://doi:10.3389/fnmol.2024.1355281
10. Asif N., Patel A., Vedantam D., Poman D. S., Motwani L. Migraine With Comorbid Depression: Pathogenesis, Clinical Implications, and Treatment. Cureus. 2022;14(6):e25998. https://doi.org/10.7759/cureus.25998
11. Grangeon L., Lange K. S., Waliszewska-Prosół M., Onan D., Marschollek K. [et al.]. Genetics of migraine: where are we now? The Journal of Headache and Pain. 2023;24(1):12. https://doi.org/10.1186/s10194-023-01547-8
12. Kaag Rasmussen M., Møllgård K., Bork P. A. R., Weikop P., Esmail, T. [et al.]. Trigeminal ganglion neurons are directly activated by influx of CSF solutes in a migraine model. Science. 2024;385(6704):80-86. https://doi.org/10.1126/science.adl0544
13. Parajulee A., Kim K. Structural studies of serotonin receptor family. BMB Reports. 2023;56(10):527-536. https://doi.org/10.5483/BMBRep.2023-0147
14. Kitamura E., Imai N. Molecular and Cellular Neurobiology of Spreading Depolarization/Depression and Migraine: A Narrative Review. International Journal of Molecular Sciences. 2024;25(20):11163. https://doi.org/10.3390/ijms252011163
15. Androulakis X. M., Yu X., Zhu X., Thiam M. A., Cai G. Migraine and major depression: localizing shared genetic susceptibility in different cell types of the nervous systems. Frontiers in Neurology. 2023;14:1254290. https://doi.org/10.3389/fneur.2023.1254290
16. Eren-Koçak E., Dalkara T. Ion Channel Dysfunction and Neuroinflammation in Migraine and Depression. Frontiers in Pharmacology. 2021;12:777607. https://doi.org/10.3389/fphar.2021.777607
17. Viudez-Martínez A., Torregrosa A. B., Navarrete F., GarcíaGutiérrez M. S. Understanding the Biological Relationship between Migraine and Depression. Biomolecules. 2024;14(2):163. https://doi.org/10.3390/biom14020163
18. Pistoia F., Salfi F., Saporito G., Ornello R., Frattale I. [et al.]. Behavioral and psychological factors in individuals with migraine without psychiatric comorbidities. The Journal of Headache and Pain. 2022;23(1):110. https://doi.org/10.1186/s10194-022-01485-x
19. Torres-Ferrús M., Ursitti F., Alpuente A., Brunello F., Chiappino D. [et al.]. From transformation to chronification of migraine: pathophysiological and clinical aspects. The Journal of Headache and Pain. 2020;21(1):42. https://doi.org/10.1186/s10194-020-01111-8
20. Amiri P., Kazeminasab S., Nejadghaderi S. A., Mohammadinasab R., Pourfathi H. [et al.]. Migraine: A Review on Its History, Global Epidemiology, Risk Factors, and Comorbidities. Front. Neurol. 2022;12:800605. https://doi.org/10.3389/fneur.2021.800605
21. Lv X., Xu B., Tang X., Liu S., Qian J. H. [et al.]. The relationship between major depression and migraine: A bidirectional two-sample Mendelian randomization study. Frontiers in Neurology. 2023;14:1143060. https://doi.org/10.3389/fneur.2023.1143060
22. Sanchez Del Rio M., Cutrer F. M. Pathophysiology of migraine aura. Handbook of Clinical Neurology. 2023;198:71-83. https://doi.org/10.1016/B978-0-12-823356-6.00016-0
23. Alwhaibi M., Meraya A. M., AlRuthia, Y. Healthcare Expenditures Associated With Comorbid Anxiety and Depression Among Adults With Migraine. Frontiers in Neurology. 2021;12:658697. https://doi.org/10.3389/fneur.2021.658697
24. Stubberud A., Buse D. C., Kristoffersen E. S., Linde M., Tronvik E. Is there a causal relationship between stress and migraine? Current evidence and implications for management. The Journal of Headache and Pain. 2021;22(1):155. https://doi.org/10.1186/s10194-021-01369-6
25. Affatato O., Dahlén A. D., Rukh G., Schiöth H. B., Mwinyi J. Assessing volumetric brain differences in migraine and depression patients: a UK Biobank study. BMC neurology. 2023;23(1):284. https://doi.org/10.1186/s12883-023-03336-x
26. Li Y., Luo G., Zhou L., Wang X., Liu H. [et al.]. Mediators of the association between depression and migraine: a mendelian randomization study. Frontiers in Genetics. 2024;15:1326817. https://doi.org/10.3389/fgene.2024.1326817
27. David M. C. M. M., Mattos M. S. B., Souto J. J. S., Brito S. A. C. F., Leite E. S. [et al.]. Changes in the rest-activity rhythm in migraine patients are associated with anxiety symptoms. Revista Brasileira de Psiquiatria. 2022;44(6):611-620. https://doi.org/10.47626/1516-4446-2021-2367
28. Cacciatore M., Raggi A., Pilotto A., Cristillo V., Guastafierro E. [et al.]. Neurological and Mental Health Symptoms Associated with Post-COVID-19 Disability in a Sample of Patients Discharged from a COVID-19 Ward: A Secondary Analysis. International Journal of Environmental Research and Public Health. 2022;19(7):4242. https://doi.org/10.3390/ijerph19074242
29. Suzuki K., Takeshima T., Igarashi H., Imai N., Danno D. [et al.]. Impact of the COVID-19 pandemic on migraine in Japan: a multicentre cross-sectional study. The Journal of Headache and Pain. 2021;22(1):53. https://doi.org/10.1186/s10194-021-01263-1
30. Hrytsenko O., Kopchak O., Kozyk M., Strubchevska K. The impact of the COVID-19 pandemic on patients with migraine. SAGE Open Medicine. 2023;11:20503121231170726. https://doi.org/10.1177/20503121231170726
31. Magdy R., Elmazny A., Soliman S. H., Elsebaie E. H., Ali S. H. [et al.]. Post-COVID-19 neuropsychiatric manifestations among COVID-19 survivors suffering from migraine: a case-control study. The Journal of Headache and Pain. 2022;23(1):101. https://doi.org/10.1186/s10194-022-01468-y
32. Irimia P., Garrido-Cumbrera M., Santos-Lasaosa S., Aguirre-Vazquez M., Correa-Fernández J. [et al.]. Impact of monthly headache days on anxiety, depression and disability in migraine patients: results from the Spanish Atlas. Scientific Reports. 2021;11(1):8286. https://doi.org/10.1038/s41598-021-87352-2
33. Lee H., Kim S., Chang M. C. Associations Between Headache (Migraine and Tension-Type Headache) and Psychological Symptoms (Depression and Anxiety) in Pediatrics: A Systematic Review and Meta-analysis. Pain Physician. 2023;26(6):617-626.
34. Zhu J., Chen J., Zhang K. Clinical effect of flunarizine combined with duloxetine in the treatment of chronic migraine comorbidity of depression and anxiety disorder. Brain and Behavior. 2022;12(8):e2689. https://doi.org/10.1002/brb3.2689
35. de Vries Lentsch S., van der Arend B. W. H., de Boer I., van Zwet E. W., MaassenVanDenBrink A. [et al.]. Depression and treatment with anti-calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies for migraine. European Journal of Neurology. 2024;31(2):e16106. https://doi.org/10.1111/ene.16106
36. Chen S. P. Migraine and treatment-resistant depression. Progress in Brain Research. 2023;281:149-173. https://doi.org/10.1016/bs.pbr.2023.05.001
37. Omaer A., Albilali A., Bamogaddam R., Almutairi F., Alsaif R. [et al.]. Improvement of comorbid anxiety and depression in patients with migraine treated with injectable preventive calcitonin gene-related peptide antagonists: Review of clinical evidence. Saudi pharmaceutical journal: SPJ: the official publication of the Saudi Pharmaceutical Society. 2024;32(4):101989. https://doi.org/10.1016/j.jsps.2024.101989
38. Caronna E., Alpuente A., Torres-Ferrus M., Pozo-Rosich P. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention. Handbook of Clinical Neurology. 2024;199:107-124. https://doi.org/10.1016/B978-0-12-823357-3.00024-0
39. Hervias T. An update on migraine: Current and new treatment options. JAAPA. 2024;37(5):1-7. https://doi.org/10.1097/01.JAA.0000000000000014
40. Mollan S. P., Subramanian A., Perrins M., Nirantharakumar K., Adderley N. J. [et al.]. Depression and anxiety in women with idiopathic intracranial hypertension compared to migraine: A matched controlled cohort study. Headache. 2023;63(2):290-298. https://doi.org/10.1111/head.14465
41. Lee W., Shin H. J., Min I. K., Kim C. S., Kim K. M. [et al.]. Shared comorbidity of depression, migraine, insomnia, and fibromyalgia in a population-based sample. Journal of Affective Disorders. 2024;354:619-626. https://doi.org/10.1016/j.jad.2024.03.077
42. McCracken H. T., Thaxter L. Y., & Smitherman T. A. Psychiatric comorbidities of migraine. Handbook of Clinical Neurology. 2024;199:505-516. https://doi.org/10.1016/B978-0-12-823357-3.00013-6
43. Demır Ü. F., Bozkurt O. Effects of Perceived Social Support, Depression and Anxiety Levels on Migraine. Noro Psikiyatri Arsivi. 2020;57(3):210-215. https://doi.org/10.29399/npa.25000
44. Pearl T. A., Dumkrieger G., Chong C. D., Dodick D. W., Schwedt T. J. Impact of Depression and Anxiety Symptoms on Patient-Reported Outcomes in Patients With Migraine: Results From the American Registry for Migraine Research (ARMR). Headache. 2020;60(9):1910-1919. https://doi.org/10.1111/head.13911

Ключевые слова: мигрень, депрессия, тревога, головная боль и тревожно-депрессивные расстройства


Учредители:
Ставропольская государственная медицинская академия
Государственный научно-исследовательский институт курортологии
Пятигорская государственная фармацевтическая академия